Introduction: Difficult Gram-negative infections are increasingly treated with new b-lactamase inhibitor combinations, e.g. ceftazidime/avibactam. Disturbingly, mutations in KPC carbapenemases can confer ceftazidime/avibactam resistance, which is sometimes selected during therapy. We explored whether this risk extended to AmpC and ESBL enzymes.
Introduction
Avibactam is the first diazabicyclooctane b-lactamase inhibitor to enter clinical use, formulated with ceftazidime and now licensed in both the USA and the EU. An aztreonam/avibactam combination is in advanced development; development of a ceftaroline combination was pursued into Phase II, but is now in abeyance. 1 Avibactam inhibits class A b-lactamases, including ESBLs and KPC types, as well as class C (AmpC) types. 2 Inhibitory activity against class D b-lactamases is variable, but few of these are potent ceftazidimases. Metallo (class B) enzymes evade inhibition. As with all b-lactamase inhibitor combinations, activity also depends on the amount of b-lactamase, the underlying spectrum of the partner b-lactam and the permeability and efflux traits of the target strain. 3, 4 Single amino acid substitutions can reduce binding of clavulanate and penicillanic acid sulphones by TEM and SHV penicillinases, 5 but in-therapy selection of sequence variants of these enzymes is very rare. 6, 7 Less is yet known on the potential of avibactam combinations to select resistance. In vitro studies with ceftaroline/ 8 yielded: (i) a single mutant of CTX-M-15 enzyme with a Lys237Gln substitution; and (ii) ceftaroline/avibactam-resistant mutants of AmpC-derepressed Enterobacter with deletions in the X-loop of AmpC, with Asn366His/Ile substitutions in AmpC, or with porin modifications. The CTX-M-15 mutant conferred resistance to ceftaroline/avibactam but lost the ability of classical CTX-M-15 to cause resistance to other oxyimino-cephalosporins; the AmpC mutants were associated with broad resistance. We failed to select stable resistance to ceftaroline/avibactam in Enterobacteriaceae with other ESBLs besides CTX-M-15 or in those with KPC blactamase. 8 More recently, in vitro and clinical selections of ceftazidime/avibactam-resistant mutants of Enterobacteriaceae with KPC carbapenemases have been described. Several mutations were seen in the laboratory mutants, mostly reconfiguring the X-loop. 9 These alterations included Asp179Tyr, which has since been selected, during ceftazidime/avibactam therapy, in clinical mutants. 10 Its effect is to increase binding of ceftazidime, 11 protecting the KPC enzyme from inactivation by avibactam. Such mutants show only small MIC rises for avibactam combinations other than ceftazidime/avibactam and often have reduced resistance to meropenem and aztreonam. 9, 10 Clinical selection of reduced susceptibility, with the ceftazidime/avibactam MIC rising from 1 to 8 mg/L, was also described in a Klebsiella pneumoniae with OXA-48 and CTX-M-14. 12 This was associated with Pro170Ser and Thr264Ile mutations in the CTX-M-14 enzyme; OXA-48, which lacks ceftazidimase activity, remained unchanged.
These observations led us to undertake selection studies with ceftazidime/avibactam, investigating a wide range of ESBL and AmpC enzymes.
Materials and methods

Test strains
The test strains are detailed in Table 1 and were either reference organisms or isolates from survey collections. 13, 14 Work centred on Escherichia coli, K. pneumoniae, Enterobacter cloacae and Citrobacter freundii, as the major opportunistic Enterobacteriaceae, and on TEM, SHV, CTX-M-15 and AmpC, as the prevalent b-lactamases of concern.
b-Lactamase types were initially identified from phenotypes and PCR, but later confirmed by WGS. Controls for MIC testing comprised E. coli ATCC 25922, E. coli ATCC 35218 and K. pneumoniae ATCC 700603.
Antibiotics
Avibactam was provided by AstraZeneca (Wilmington, DE, USA), as were ceftazidime and ceftaroline; other antimicrobials were obtained from Sigma (Poole, UK), except ertapenem (Merck Sharp & Dohme, Hoddesdon, UK) and meropenem (AstraZeneca, Alderley Park, UK).
Single-step mutant selection
Selection was undertaken as previously described for ceftaroline/avibactam. 8 Briefly, 10 9 cfu from an overnight broth culture were spread on Mueller-Hinton agar (Thermo Fisher/Oxoid, Basingstoke, UK) containing ceftazidime/avibactam (fixed 1 or 4 mg/L concentration) at 2-16% the MIC found previously by CLSI agar dilution. Colonies were counted after overnight incubation and representatives retained for MIC determination and sequencing. Dilutions of the same overnight nutrient broth cultures were serially diluted and spread onto antibiotic-free Mueller-Hinton agar to provide a viable count, as a denominator for calculation of mutation frequencies.
Multi-step selection using b-lactamase producers Inocula of 10 8 cfu were added to 10 mL amounts of nutrient broth containing ceftazidime/avibactam (with avibactam at 1 or 4 mg/L) at the ceftazidime/avibactam MICs found previously on agar with the same avibactam concentration, but otherwise by standard CLSI methodology, and incubated for up to 48 h. 8 This was repeated sequentially, each time doubling the ceftazidime concentration, but keeping the avibactam concentration unchanged.
Selectivity for AmpC-derepressed mutants
Like other oxyimino-cephalosporins, ceftazidime can select AmpCderepressed mutants from AmpC-inducible populations. 15 To test how avibactam might affect this phenomenon we plated 10 9 cfu of ceftazidime-susceptible (i.e. WT, AmpC-inducible, MIC 2 mg/L) cells of E. cloacae or C. freundii onto Mueller-Hinton agar with ceftazidime at 8% MIC with or without 1 or 4 mg/L avibactam. After overnight incubation the colonies were counted and mutant frequencies calculated relative to the viable counts contained in the inocula.
MIC determinations
MICs were determined by CLSI agar dilution 16 for antibiotics alone, or in combination with b-lactamase inhibitors at the concentrations specified in parentheses: ceftazidime, ceftazidime/avibactam (1 and 4 mg/L), ceftazidime/cloxacillin (100 mg/L), ceftazidime/clavulanate (4 mg/L), ceftazidime/ tazobactam (4 mg/L), ceftaroline, ceftaroline/avibactam (4 mg/L), cefotaxime, cefepime, piperacillin/tazobactam (4 mg/L), ertapenem, meropenem, gentamicin and ciprofloxacin.
Genomic sequencing and bioinformatics analysis
Parent and mutant DNA were fragmented and tagged for multiplexing using Nextera XT Library Preparation Kits (Illumina, Cambridge, UK) and sequenced on an Illumina HiSeq platform to produce 2%100 bp reads. Reads were assembled de novo using VelvetOptimiser software (http:// www.vicbioinformatics.com/software.velvetoptimiser.shtml) with k-mer values from 55 to 75. The presence of b-lactamase variants was confirmed by BLAST searches, using the newly assembled genomes as query sequences against a reference database downloaded from the NCBI b-Lactamase Data Resources website (https://www.ncbi.nlm.nih.gov/pathogens/beta-lac tamase-data-resources).
Genomic alterations in mutants were identified as previously described. 17 Sequencing reads for mutants were mapped to the de novo assembled genome of the corresponding parent using Bowtie 2 (http://bow tie-bio.sourceforge.net/bowtie2) and variants were called using SAMtools with default paramters. 18 The variant-calling files thereby generated were then parsed line by line to determine apparent alterations, with the accuracy of these predictions assessed based on read depth and mapping quality, as described previously. 17 Sequences flanking confirmed alterations for 2-5 kb on either side were extracted from the parent assemblies and manually inspected for gene structure and functional annotation with BLAST searches so as to determine whether the detected changes were located in an ORF, promoter, or intergenic region. Changes within structural genes were confirmed by aligning the protein-encoding sequences extracted from the parent and mutant assemblies. In high-throughput sequencing, reads are randomly sampled, meaning that the number of reads for any gene or gene fragment reflects its copy number. We therefore counted the number of reads that mapped to the b-lactamase genes relative to those for the single-copy chromosomal gyrA and parC genes, thereby assessing whether the b-lactamase genes had been amplified in the mutants. Parent and mutant sequencing data are deposited in the European Nucleotide Archive under study number PRJEB27344 (www.ebi. ac.uk/ena).
Ceftazidime/avibactam-resistant mutants
JAC
Results
Mutant selection frequencies
Mutants were obtained from most strains, including b-lactamasenegative controls, when using ceftazidime/avibactam (1 mg/L) at 2% MIC, with frequencies of 10 #7 -10 #9 (Table 1) . Mutant frequencies were much reduced at higher MIC multiples or with 4 mg/L avibactam in the selective medium. With 8-or 16-fold MIC multiples, mutants were obtained only from strains with stably derepressed AmpC; none was detected from ESBL producers or controls, even when the avibactam concentration was only 1 mg/L. Attempts to 'train' highly resistant mutants by multi-step procedures in broth were unsuccessful, with few mutants obtained; again mostly from strains with stably derepressed AmpC b-lactamases.
Mutants of AmpC-derepressed strains
MICs were determined for 53 mutants selected from AmpCderepressed E. cloacae or C. freundii. The MICs of ceftazidime/avibactam (4 mg/L) rose from 0.5-2 mg/L for the parent strains to 4-64 (mostly 8-16) mg/L for the mutants; in 23/53 cases the values for the mutants were .8!4 mg/L, thus exceeding the CLSI/ EUCAST breakpoint. MICs of ceftazidime combined with 100 mg/L cloxacillin (which inhibits AmpC) also were widely, though not universally, raised; MICs of ceftaroline/avibactam rose little, generally only from 0.25-2 mg/L to 1-2 mg/L. Shifts in the MICs of other b-lactams were erratic; some mutants showed rises in cefotaxime and cefepime MICs, whereas others showed falls. Likewise, a few mutants showed increases in ertapenem MIC, but falls were more common.
This diversity is illustrated in Table 2 for the 10 mutants of AmpC-derepressed E. cloacae and C. freundii selected for WGS. All proved to have modifications in ampC, resulting in amino acid substitutions, including Arg168Pro (three representatives), Arg168His (two representatives), Gly176Arg/Asp (one representative each), Asn366Tyr (one representative) or two to four amino acid deletions around positions 309-314 (two representatives; one also with Leu133Met). The Arg168Pro substitution was associated with reduced resistance to all cephalosporins in both E. cloacae and C. freundii, along with the complete loss of synergy between avibactam and both ceftazidime and ceftaroline, whereas Arg168His and Gly176Arg/Asp were associated with retention of broad cephalosporin resistance and ceftaroline/avibactam synergy coupled with markedly reduced ceftazidime/avibactam synergy.
Characterization of selected mutants: ESBL producers
Among 63 mutants of nine ESBL producers (the tenth failed to yield any mutants), only 12 achieved resistance to ceftazidime/avibactam as defined by CLSI, with MICs of 16!4 or 32!4 mg/L. All these 12 were selected from the same parent, E. coli J53-1 with TEM-10 ceftazidimase. The ceftazidime/avibactam MICs for other Livermore et al. Table 2 . Characterization of mutants selected from AmpC-derepressed E. cloacae and C. freundii The first 20 amino acids comprise a signal peptide, cleaved from the mature protein and are discounted in some numberings.
Ceftazidime/avibactam-resistant mutants JAC mutants were raised, but with values 8!4 mg/L. MICs for 19 mutants selected to represent phenotype diversity are shown in Table 3 , along with details of the genetic modifications revealed by WGS. Most mutants of ESBL producers had sequence changes in genes related to permeability, efflux or b-lactamase expression, not in b-lactamase-coding genes. Thus: 7/19 had modifications in ompR/envZ, which regulates expression of porins OmpC and OmpF; 20 2/19 had identical alterations in acrAB efflux gene components; and 9/19 either yielded increased reads of b-lactamase genes relative to gyrA and parC during WGS, implying b-lactamase gene amplification, or had sequence changes upstream of blactamase genes that putatively might increase their expression, though this was not investigated by experiment. Almost all these mutants of ESBL producers showed broad rises for b-lactam MICs, including other inhibitor combinations besides ceftazidime/avibactam. A representative ('mutant 5') of the group of E. coli J53-1 TEM-10 mutants with ceftazidime/avibactam MICs of 16!4 mg/L (i.e. the most resistant mutants selected from ESBL producers, see above) had changes in both envZ and upstream of bla TEM ; MICs of 4!4 mg/L were recorded for mutants 2, 3 and 4 of the same parent and these only had the lesion upstream of bla TEM , not that in envZ.
Just 1 of the 19 mutants sequenced-E. coli EO 553 mutant 3-had a lesion in its ESBL-encoding gene, leading to an Asp182Tyr substitution in CTX-M-15. Compared with its parent, this mutant lost resistance to ceftaroline, cefotaxime and cefepime, and the ceftazidime MIC was reduced 2-fold from 32 to 16 mg/L. Synergy was completely lost between ceftazidime and clavulanate or tazobactam, whilst the ceftazidime/avibactam MIC rose 8-fold, from 0.25 to 2 mg/L.
One further mutant-mutant 9 of K. pneumoniae Mei 838-had a lesion in mdrA, which encodes PBP2. This may act as a secondary target for diazabicyclooctanes, though this effect is much weaker for avibactam than for the developmental analogues nacubactam and zidebactam. 21, 22 The significance of this lesion is difficult to judge.
Finally, several mutants had changes in proteins with no obvious link to b-lactam or diazabicyclooctane action, including: (i) aspartate semialdehyde dehydrogenase (mutant 7 of K. pneumoniae Mei 838); (ii) 4-cytidine-5 0 -diphospho-2-C-methyl-D-erythritol kinase and putative sulphate transporter (both in mutant 8 of K. pneumoniae Mei 838); and (iii) the DNA-binding protein HLP-II pleiotropic regulator (mutant 14 of K. pneumoniae Mei 254).
Mutants from control Enterobacteriaceae lacking ceftazidime resistance
Mutants of ceftazidime-susceptible E. coli and K. pneumoniae were obtained under selection with ceftazidime/avibactam (1 mg/L), though not ceftazidime/avibactam (4 mg/L) ( Table 1) These observations led us to investigate the effect of avibactam on the selectivity of ceftazidime for AmpC-derepressed mutants from the AmpC-inducible populations of E. cloacae and C. freundii. We plated five AmpC-inducible, ceftazidime-susceptible strains of each of these species onto agar with ceftazidime alone or with avibactam at 1 or 4 mg/L, always at 8% MIC. Large numbers of colonies were recovered on plates containing ceftazidime alone, indicating mutation frequencies of 10
, as is typical for these species. 23 With avibactam at 1 mg/L, the numbers of colonies that grew were reduced by .75% in all cases and, for 8/10 strains, fell below the detection limit of 10
#9
; with avibactam at 4 mg/L, the mutation frequency fell below 10 #9 for 9/10 strains.
Discussion
Mutational resistance to ceftazidime/avibactam has become a concern in respect of isolates with KPC carbapenemases, with reports of resistance emerging during therapy as well as in vitro. 9, 10 In the light of this concern we explored whether ceftazidime/avibactam could also select resistant mutants from AmpCderepressed Enterobacteriaceae and ESBL producers; the work followed a similar previous study for ceftaroline/avibactam. 8 We included common and representative ESBLs carried by E. coli and K. pneumoniae, specifically: CTX-M-15, as the most prevalent type; CTX-M-1, as common from animal isolates; SHV-2 and -5, as major ESBL mutants of SHV-1; and TEM-10, as a ceftazidimase-type ESBL. E. cloacae and C. freundii were prioritized as the major species where high-level expression AmpC is a resistance issue. Clearly there are further enzymes that merit investigation in the future, notably including group 9 CTX-M types (CTX-M-9 or -14), which are globally frequent, and broad-spectrum TEM ESBLs (e.g. TEM-3).
Unlike for KPC carbapenemases, where we found much higher mutation frequencies to ceftazidime/avibactam than to ceftaroline/avibactam, 8, 9 the present data substantially mirror those obtained with ceftaroline/avibactam, with: (i) low mutation frequencies (,10 #8 at above 2% MIC), particularly when selection was done with 4 mg/L avibactam; (ii) mostly small rises in ceftazidime/avibactam MICs, rather than frank resistance; and (iii) most emerging resistance seen among AmpC-derepressed strains rather than those with ESBLs.
Critically, and also in keeping with the previous ceftaroline/avibactam work, we found that the mutants of AmpC-derepressed strains typically had changes within ampC, whereas mutants derived from ESBL producers largely had mutations affecting efflux, permeability or, putatively, b-lactamase quantity. Nevertheless, there were differences: hot spots for mutations associated here with ceftazidime/avibactam non-susceptibility in Livermore et al. Table 3 . 
Continued
Ceftazidime/avibactam-resistant mutants JAC Table 3 . (and Gly176Arg/Asp) raised ceftazidime/avibactam MICs, but had little effect on cephalosporin resistance overall or on synergy between ceftaroline and avibactam-behaviours that are more compatible with the mutation conferring increased affinity for ceftazidime. The substitutions were all at conserved positions, with a caveat that the background variation among the primary sequences of AmpC b-lactamases from E. cloacae was about 40% in one study. 24 Asn366 (designated as Asn346 in Lahiri et al. 24 after discounting the 20 amino acid signal peptide) has previously been described as a key residue for avibactam binding. 24 The deletions around positions 309-314 observed here are in helix H10, close to the enzyme active site, and at the location where a 6-amino-acid deletion in clinical isolate E. cloacae CHE was associated with expansion of the enzyme's activity and diminished susceptibility to avibactam combinations. 19 The sole mutant of an ESBL enzyme selected here was an Asp182Tyr variant of CTX-M-15. This change was associated with the reduction or loss of resistance to other cephalosporins besides ceftazidime. It seems unlikely that a mutant with such a narrowed resistance spectrum would be successful in evolutionary terms, implying little public health risk. Similar points were made previously in respect of a Lys237Gln mutant selected with ceftaroline/ avibactam; 8 compared with its parent organism this gained ceftaroline/avibactam resistance but lost resistance to other oxyimino-cephalosporins including ceftazidime. The other mutants selected in the present study from ESBL producers largely had efflux or permeability modifications, or had mutations and amplifications suggesting increased b-lactamase expression-a known general correlate with reduced susceptibility to b-lactam/ b-lactamase inhibitor combinations. 4 Mutants selected from cephalosporin-susceptible AmpC and ESBL-negative E. coli and K. pneumoniae only showed small increases in ceftazidime/avibactam MICs and were not characterized in detail. Again, however, their antibiograms suggested permeation-or efflux-related changes. By contrast, most of the E. cloacae mutants had antibiograms suggesting AmpC derepression. Although avibactam inhibits this enzyme, MICs of ceftazidime/avibactam for AmpC-derepressed organisms are not quite so low as for AmpC-inducible ones and there appears to be a small concentration window (as, for example, with cefepime) 25 in which derepressed mutants may be selected, though these remain susceptible to ceftazidime/avibactam at breakpoint in the absence of further changes to ampC itself.
Only clinical experience will show whether the present observations have clinical significance. Overall, they suggest that the potential for emerging resistance to ceftazidime/avibactam is greater with AmpC producers than ESBL producers. Thus far we are unaware of any reports of emerging resistance during clinical use against AmpC producers. There is a single report 12 of emerging resistance in a pneumonia patient, with a K. pneumoniae producing OXA-48 carbapenemase together with CTX-M-14, an ESBL not studied here. The patient was treated first with ceftazidime plus colistin and later, after the ceftazidime MIC had risen from 4 to .256 mg/L, with ceftazidime/avibactam plus meropenem. During this latter phase of therapy the ceftazidime/avibactam MIC rose from 1 to 8 mg/L and the CTX-M-14 enzyme acquired Pro170Ser and Thr264Ile substitutions, whilst the OXA-48 carbapenemase remained unaltered. This one case must, however, be set against the clinical trials, where ESBL producers were well represented, without emerging resistance; [26] [27] [28] these support our view that the selection risk with ESBL producers is low, whereas that with AmpCderepressed organisms will only be clarified by clinical experience.
